Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for rare and metabolic diseases. With a strong pipeline and a focus on improving patient outcomes and reducing treatment burdens, the company is well-positioned for success in the biopharmaceutical industry. Revenue and value creation depend on the successful development and regulatory approvals of its drug candidates, which have shown strong efficacy signals and potential peak sales in the hundreds of millions. A positive readout from the upcoming pivotal study for its lead candidate, ersodetug, could lead to a significant increase in stock price, making Rezolute an attractive investment opportunity.

Bears say

Rezolute is currently in the clinical stage of its pipeline, with potential revenues and value creation hinging on successful product development and regulatory approvals. Interim Phase 3 results for ersodetug in tumor hyperinsulinism have given the company a positive outlook, with potential distinct approval pathway from CHI. However, with a price target of $11/share and sensitivity tables showing a $400k-600k annual list price for cHI, financials suggest that the current price may not accurately reflect the company's underlying value.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.